Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Stage IA Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02023021
• Other study ID #: ABX-1312129-8
• Status: Completed
• Phase: Phase 2
• Start date: January 2014
• Est. completion date: January 2019

Study information

• Verified date: February 2019
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pancreatic cancer has an extremely poor prognosis with a 5-year survival rate of less than 5%. About 25% of patients have the opportunity for radically surgical resection when diagnosis. However, the recurrence rate is up to 85% within 2 years. Data from clinical trials indicated that gemcitabine-based adjuvant chemotherapy reduced recurrence and enhanced overall survival for patients who have undergone surgery to remove their tumor. Nab-paclitaxel could enhance the intratumoral concentration of gemcitabine; recent studies showed that nab-paclitaxel plus gemcitabine significantly improved progression-free survival and overall survival of metastatic pancreatic cancer patients. The present study is intended to investigate the activity and safety of the combination of gemcitabine and nab-paclitaxel as adjuvant chemotherapy in treating patients with pancreatic cancer after curative resection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: January 2019
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Signed informed content obtained prior to treatment

• Age = 18 years and = 75 years

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Patients must have histologically confirmed pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant) after curative resection (R0). The pathological staging does not exceed the stage IIB.

• No tumor lesions are seen by abdominal and thoracic CT scan 4~8 weeks after surgery, and no serious adverse events are occurred during this period

• The expected survival after surgery = 6 months

• White blood cell (WBC) = 3 × 109/L; Absolute neutrophil count (ANC) = 1.5 × 109/L; Platelets (PLT) = 100 × 109/L; Hemoglobin (Hgb) = 9 g/dL

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) = 2.5 × institutional upper limit of normal (ULN); Total bilirubin (TBIL) = ULN; Creatinine (CRE) = 1.5 × ULN

• Prothrombin time (PT) and international normalized ratio (INR) = 1.5 × ULN

Exclusion Criteria:

• Active second primary malignancy or history of second primary malignancy within the last 3 years

• Patients who have received any form of anti-tumor therapy before surgery, including chemotherapy, radiotherapy, interventional chemoembolization, radiofrequency ablation, and molecular targeted therapy

• Use of any other investigational agents

• Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, internal hemorrhage, pancreatic leakage, bile leakage, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• History of allergic reactions attributed to compounds of similar chemical or biological composition to nab-paclitaxel or gemcitabine

• Metabolic acidosis, acute or chronic, including ketoacidosis

• Pregnant or nursing women

• Human immunodeficiency virus (HIV)-positive patients

• Patients who are unwilling or unable to comply with study procedures

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Neoplasms
• Stage IA Pancreatic Adenocarcinoma
• Stage IB Pancreatic Adenocarcinoma
• Stage IIA Pancreatic Adenocarcinoma
• Stage IIB Pancreatic Adenocarcinoma

Intervention

Drug:
• nab-paclitaxel
Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
• gemcitabine
Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Locations

Country	Name	City	State
China	Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University. Shanghai, China	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xian-Jun Yu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival at one year after curative resection	To evaluate the therapeutic efficacy of nab-paclitaxel plus gemcitabine chemotherapy in terms of recurrence-free survival in patients with pancreatic cancer at one year after curative resection. Computed tomography (CT) scan	From date of enrollment (after curative resection) until the date of first documented recurrence or date of death from any cause, whichever came first, assessed 2 months during therapy and 3 months thereafter up to 24 months
Secondary	Overall survival after curative resection	To evaluate the overall survival of patients (after curative resection) treated with this regimen. Outpatient visit, phone interview	From date of enrollment (after curative resection) until the date of death from any cause, assessed one month during therapy and 3 months thereafter up to 24 months
Secondary	Quality of life score after curative resection	To evaluate the quality of life score of patients (after curative resection) treated with this regimen. Outpatient visit, phone interview	One month during therapy and 3 months thereafter up to 24 months
Secondary	Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0	To evaluate the occurrence of grade 3 and 4 toxicities according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE; version 4.0) in patients treated with this regimen. The toxicity profile includes but not limits neutropenia, thrombocytopenia, peripheral neuropathy, hypoglycemia, metabolic acidosis (acute or chronic, including ketoacidosis), which will be summarized as the percentage of patients by type and grade according to treatment group. Outpatient visit, laboratory findings	One week during therapy and 3 months thereafter up to 24 months
Secondary	CA199 level after curative resection	To evaluate the CA199 level of patients (after curative resection) treated with this regimen. Outpatient visit, laboratory findings	One month during therapy and 3 months thereafter up to 24 months